{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Actavis+Inc.",
    "query": {
      "sponsor": "Actavis Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 82,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Actavis+Inc.&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T16:04:42.414Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01188057",
      "title": "A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG",
          "type": "DRUG"
        },
        {
          "name": "NIRAVAM TM 2 mg orally disintegrating tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-07",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2010-08-25",
      "last_synced_at": "2026-09-28T16:04:42.414Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188057"
    },
    {
      "nct_id": "NCT00865111",
      "title": "A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Bupropion 150 mg Extended-Released Tablet, single dose",
          "type": "DRUG"
        },
        {
          "name": "Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 26,
      "start_date": "2006-03",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2010-08-16",
      "last_synced_at": "2026-09-28T16:04:42.414Z",
      "location_count": 1,
      "location_summary": "Fort Myers, Florida",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865111"
    },
    {
      "nct_id": "NCT00759902",
      "title": "Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "morphine sulfate extended-release capsules",
          "type": "DRUG"
        },
        {
          "name": "KADIAN (morphine sulfate extended-release) capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2006-08",
      "completion_date": "2006-10",
      "has_results": true,
      "last_update_posted_date": "2010-08-17",
      "last_synced_at": "2026-09-28T16:04:42.414Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00759902"
    },
    {
      "nct_id": "NCT03499873",
      "title": "Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac 0.3% Oph Susp",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac 0.3% Oph Susp (reference)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 448,
      "start_date": "2018-03-28",
      "completion_date": "2018-12-18",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-09-28T16:04:42.414Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03499873"
    },
    {
      "nct_id": "NCT00865943",
      "title": "A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Citalopram HBr eq. 10 mg tablets, single dose",
          "type": "DRUG"
        },
        {
          "name": "CELEXATM 10 mg tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2003-07",
      "completion_date": "2003-08",
      "has_results": false,
      "last_update_posted_date": "2010-08-17",
      "last_synced_at": "2026-09-28T16:04:42.414Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865943"
    },
    {
      "nct_id": "NCT01962987",
      "title": "A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "Diclofenac sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 476,
      "start_date": "2013-03",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2020-07-20",
      "last_synced_at": "2026-09-28T16:04:42.414Z",
      "location_count": 31,
      "location_summary": "Fremont, California • Long Beach, California • Newport Beach, California + 27 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Ramon",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962987"
    },
    {
      "nct_id": "NCT03301649",
      "title": "Clinical Endpoint Study of Ivermectin 0.5% Lotion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head Lice"
      ],
      "interventions": [
        {
          "name": "Generic Ivermectin Lotion 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Sklice® (Ivermectin) Lotion 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Lotion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 905,
      "start_date": "2017-10-07",
      "completion_date": "2018-03-12",
      "has_results": true,
      "last_update_posted_date": "2019-12-20",
      "last_synced_at": "2026-09-28T16:04:42.414Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03301649"
    },
    {
      "nct_id": "NCT00864604",
      "title": "Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Nabumetone 750 mg tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2007-04",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2020-01-07",
      "last_synced_at": "2026-09-28T16:04:42.414Z",
      "location_count": 1,
      "location_summary": "Morrisville, North Carolina",
      "locations": [
        {
          "city": "Morrisville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00864604"
    },
    {
      "nct_id": "NCT00865657",
      "title": "A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Alprazolam 3 mg Extended Release Tablets, single dose",
          "type": "DRUG"
        },
        {
          "name": "XANAX XR® 3 mg tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2005-09",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2010-08-17",
      "last_synced_at": "2026-09-28T16:04:42.414Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865657"
    },
    {
      "nct_id": "NCT03287791",
      "title": "A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Generic Azelaic Acid Foam",
          "type": "DRUG"
        },
        {
          "name": "Finacea® (Azelaic Acid) Foam",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Foam",
          "type": "DRUG"
        },
        {
          "name": "Cleanser",
          "type": "OTHER"
        },
        {
          "name": "Sunscreen",
          "type": "OTHER"
        },
        {
          "name": "Towel",
          "type": "OTHER"
        },
        {
          "name": "Moisturizing Lotion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 924,
      "start_date": "2016-07-19",
      "completion_date": "2017-06-22",
      "has_results": true,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-09-28T16:04:42.414Z",
      "location_count": 26,
      "location_summary": "Encino, California • La Mesa, California • Brandon, Florida + 20 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03287791"
    }
  ]
}